ESALF - Eisai shares rise after DAYVIGO's Hong Kong launch

Eisai shares climb (ESALF) more than 10% on the back of announcing that its Hong Kong subsidiary launched its orexin receptor antagonist DAYVIGO (lemborexant) for the treatment of adults with insomnia.Eisai received approval for DAYVIGO in Hong Kong in February, and this launch is the first for DAYVIGO in Asia outside of Japan.DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R).Eisai shares are up more than 40% YTD.

For further details see:

Eisai shares rise after DAYVIGO's Hong Kong launch